Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Renalytix chair Julian Baines to step down at year-end

On 28 September 2026 Renalytix plc (LSE:RENX), a precision medicine diagnostics company focused on kidney disease, announced that its non-executive chair, Julian Baines MBE, intends to step down with effect from 31 December 2026.

Ankur Sharma | 29 September 2026

Why Did IXICO PLC LSE:IXI Rise 4.00% Amid a Firmer Tone Across London-Listed Neuroimaging Shares?

IXICO PLC — LSE:IXI closed 4.00% higher on29 September 2026, with the shares at 7.80p after a gain of 0.30p on the day.

Ishan Mudgal | 29 September 2026

Why Did Physiomics PLC LSE:PYC Rise 0.76% Amid a Firmer Tone Across London-Listed Biosciences Shares?

Physiomics PLC — LSE:PYC closed 0.76% higher on29 September 2026, with the shares at 0.529p after a gain of 0.004p on the day.

Ishan Mudgal | 29 September 2026

Why Did Provexis PLC LSE:PXS Fall 7.11% Amid a Softer Tone Across London-Listed Nutrition Science Shares?

Provexis PLC — LSE:PXS closed 7.11% lower on29 September 2026, with the shares at 0.836p after a decline of 0.064p on the day.

Ishan Mudgal | 29 September 2026

Why Did TruSpine Technologies PLC LSE:TRUE Rise 1.11% Amid a Firmer Tone Across London-Listed Medical Device Shares?

TruSpine Technologies PLC — LSE:TRUE closed 1.11% higher on29 September 2026, with the shares at 3.10p after a gain of 0.03p on the day.

Ishan Mudgal | 29 September 2026

How International Biotechnology Trust (LSE:IBT) Benefited From a Run of Biotech Takeovers in Its Portfolio

International Biotechnology Trust PLC is a London-listedInvestmenttrust that invests in biotechnology and related companies. Its portfolio managers are Ailsa Craig and Marek Poszepczynski, with Schroder Investment Management Limited acting as alternative investmentFund Managerand company secretary. The trust also holds interests inVenture Capitalfunds managed by …

Ankur Sharma | 29 September 2026

Hemogenyx Pharmaceuticals posts £6.56m H1 loss as cash stands at £4.58m after £5.6m raise

Hemogenyx (LSE:HEMO), a biopharmaceutical company developing treatments for blood diseases whose shares are listed in the transition category of the Official List, published unaudited half-year results for the six months to 30 June 2026 on 28 September 2026.

Ankur Sharma | 29 September 2026

TheraCryf reveals it rejected non-binding bid for lead assets as FY loss reaches £3.5m

TheraCryf (LSE:TCF), an AIM-quoted biotechnology company developing medicines for addiction and neuropsychiatric disorders, published its final results for the year to 31 March 2026 on 28 September 2026.

Ankur Sharma | 29 September 2026

Coiled Therapeutics reports 80% clinical benefit rate in AO-252 Phase I; H1 cash £5.1m

Coiled Therapeutics plc (LSE:COIL), which is also traded on the US OTCQB market, published interim results for the six months to 30 June 2026 on 28 September 2026.

Ankur Sharma | 29 September 2026

4basebio lifts H1 sales orders 210% to £1.2m and adds opDNA supply role alongside TriLink

4basebio PLC (LSE:4BB), the AIM-quoted, Cambridge-based company, published two announcements on 28 September 2026. The first was its unaudited half-year report for the six months ended 30 June 2026. The second set out aPartnershipunder which 4basebio will supply clinical-grade opDNA synthetic DNA starting material …

Ankur Sharma | 29 September 2026
Support

Hi! How can we help you today?

Loading…